The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study.

ABSTRACT:

Objective

The prognostic value of body mass index (BMI) in metastatic breast cancer (MBC) has not been fully elucidated. In a prospective study to investigate the chemo-sensitizing effect of statins on clinical outcomes in MBC patients who were scheduled to receive palliative chemotherapy (Carboplatin and Vinorelbine), we sought to investigate the relationship between baseline BMI and clinical outcomes; response, overall survival (OS) and progression free survival (PFS), over a median follow-up of 40-months.

Results

Eighty-Two MBC patients were enrolled and categorized using baseline BMI as underweight (BMI, < 18.5 kg/m², n = 1), normal-weight (BMI, 18.5-24.9 kg/m², n = 20), overweight (BMI, 25-29.9 kg/m², n = 34), and obese (BMI, ≥ 30 kg/m

SUBMITTER: Alarfi H 

PROVIDER: S-EPMC5667491 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature